Overall rank by patents
#26,249
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 8 technology areas, active 2015–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: H02H (EMERGENCY PROTECTIVE CIRCUIT ARRANGEMENTS).
The verdict
Emprimus holds 10 US patents across 8 technology areas, rank #26,249 of 50,000 tracked assignees.
Emprimus, Llc has been granted 10 US utility patents between 2015 and 2022, placing Emprimus, Llc at rank #26,249 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.5 claims per patent with primary concentration in H02H (EMERGENCY PROTECTIVE CIRCUIT ARRANGEMENTS). As a US Corporation, Emprimus, Llc is one of the more focused assignees in the PatentsView dataset. By volume, Emprimus sits between Ellodi Pharmaceuticals, L.p. (10 patents, rank #26,245) and Enforcement Video, Llc (10 patents, rank #26,253) - the closest US assignees by grant volume. The composite Innovation Score of 34.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 1 grants, compared with 9 in the 2015–2019 window, a -89% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Emprimus, Llc's 16.5 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 8 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Emprimus, Llc against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Ellodi Pharmaceuticals, L.P.
10 patents
Elmdene Group, Ltd.
10 patents
Elmo Co., Ltd.
10 patents
Emerald Energy NW, LLC
10 patents
EnChroma, Inc.
10 patents
Endophys Holdings, LLC
10 patents
Energy Integration, Inc.
10 patents
Enforcement Video, LLC
10 patents
Emprimus, LLC
10 patents
What this shows Emprimus holds 10 patents at rank #26,249, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Emprimus's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
35 Top 51% higher than 49% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 30.0% |
| 2016 | 1 | 10.0% |
| 2017 | 3 | 30.0% |
| 2018 | 1 | 10.0% |
| 2019 | 1 | 10.0% |
| 2022 | 1 | 10.0% |
Top 8 of 8 technology areas
Overall rank by patents
#26,249
Across all tracked assignees
34.9 out of 100
How to use this portfolio
Emprimus's 10 grants land it in the top 51% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.